Motugivatrep

Motugivatrep
Clinical data
Trade names	Avarept
Other names	SJP-0132; DA-55647; HY-145582; CS-0376446; D12841
Legal status
Legal status	Rx in Japan;
Identifiers
	IUPAC name (2E)-N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-2-[7-(trifluoromethyl)-2,3-dihydrochromen-4-ylidene]acetamide;
CAS Number	920332-28-1 ;
PubChem CID	137350798 ;
UNII	7SHP2FH6HQ ;
KEGG	D12841 ;
ChEMBL	ChEMBL5095073 ;
Chemical and physical data
Formula	C22H20F3NO3
Molar mass	403.401 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CC2=C(C[C@@H]1O)C(=CC=C2)NC(=O)/C=C/3\CCOC4=C3C=CC(=C4)C(F)(F)F;
	InChI InChI=1S/C22H20F3NO3/c23-22(24,25)15-5-7-17-14(8-9-29-20(17)11-15)10-21(28)26-19-3-1-2-13-4-6-16(27)12-18(13)19/h1-3,5,7,10-11,16,27H,4,6,8-9,12H2,(H,26,28)/b14-10+/t16-/m1/s1; Key:MAWBBYZCTDJMDD-HFQYIWAZSA-N;

Last updated January 12, 2026

Motugivatrep (brand name Avarept) is an ophthalmic drug. It Japan, it is approved to treat dry eye disease.^[1]

It acts as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist.^[2]

References

↑ "Approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition". firstwordpharma.com. December 22, 2025.
↑ Hori Y, Wada T, Omatsu K, Arita R, Dannoue K, Fukuoka S, et al. (SJP-0132 clinical study investigators) (December 2025). "Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study". American Journal of Ophthalmology. 283: 163–175. doi:10.1016/j.ajo.2025.11.036. PMID 41352685.

This ophthalmology article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition". firstwordpharma.com. December 22, 2025.

[2] Hori Y, Wada T, Omatsu K, Arita R, Dannoue K, Fukuoka S, et al. (SJP-0132 clinical study investigators) (December 2025). "Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study". American Journal of Ophthalmology. 283: 163–175. doi:10.1016/j.ajo.2025.11.036. PMID 41352685.

[1]

[2]